Thubrikar Aortic Valve, Inc.
Our next-gen Transcatheter Aortic Valve Implantation (TAVI) device was designed after nature's valve and demonstrates preclinical superiority (Durability, etc.)
Dr. Mano Thubrikar designed Optimum TAV after the natural aortic valve to address the limitations of current valves. Optimum TAV surpassed 890 Million cycles (simulates > 24 years in vivo) in a durability test, and has been successfully deployed by our delivery catheters in 20 sheep. The Company will sponsor an FIH study in 2018, Licensees in Brazil and China will sponsor full trials starting 2018 and 2019, respectively, and provide royalties.